Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3903 ARTÍCULOS , VIENDO DEL 466 AL 480

Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?

Lima MM, Targa AD, Noseda AC, Rodrigues LS, Delattre AM, dos Santos FV, Fortes MH, Maturana MJ, Ferraz AC.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):418-28. doi: 10.2174/18715273113126660155.

Alzheimer disease and type 2 diabetes mellitus: the link to tyrosine hydroxylase and probable nutritional strategies

Aliev G, Shahida K, Gan SH, Firoz C, Khan A, Abuzenadah AM, Kamal W, Kamal MA, Tan Y, Qu X, Reale M.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):467-77. doi: 10.2174/18715273113126660153.

Evidence of pre-synaptic dopaminergic deficit in a patient with a novel progranulin mutation presenting with atypical parkinsonism

Carecchio M, Galimberti D, Fenoglio C, Serpente M, Scarpini E, Comi C, Terazzi E, Cantello R.

J Alzheimers Dis. 2014;38(4):747-52. doi: 10.3233/JAD-131151.

Safety of veralipride for the treatment of vasomotor symptoms of menopause

Valencia MH, Arias Mde J, González CC, Marín IH, González JH, Campos ER, Rodríguez MA, Álvarez IM, Vargas MA, Flores JB, Haro SS, Bonilla MC, Escudero RB, Campero RA.

Menopause. 2014 May;21(5):484-92. doi: 10.1097/GME.0b013e3182a46dcb.

Modulation of cell death in age-related diseases

Tezil T, Basaga H.

Curr Pharm Des. 2014;20(18):3052-67. doi: 10.2174/13816128113196660702.

Can BACE1 inhibition mitigate early axonal pathology in neurological diseases?

Yan XX, Ma C, Gai WP, Cai H, Luo XG.

J Alzheimers Dis. 2014;38(4):705-18. doi: 10.3233/JAD-131400.

Pathogenesis-targeted, disease-modifying therapies in Parkinson disease

AlDakheel A, Kalia LV, Lang AE.

Neurotherapeutics. 2014 Jan;11(1):6-23. doi: 10.1007/s13311-013-0218-1.

Approaches for neural tissue regeneration

Binan L, Ajji A, De Crescenzo G, Jolicoeur M.

Stem Cell Rev Rep. 2014 Feb;10(1):44-59. doi: 10.1007/s12015-013-9474-z.

Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration

Osellame LD, Duchen MR.

Br J Pharmacol. 2014 Apr;171(8):1958-72. doi: 10.1111/bph.12453.

Unravelling mitochondrial pathways to Parkinson's disease

Celardo I, Martins LM, Gandhi S.

Br J Pharmacol. 2014 Apr;171(8):1943-57. doi: 10.1111/bph.12433.

Neuropathology of parkinsonism in patients with pure Alzheimer's disease

Horvath J, Burkhard PR, Herrmann FR, Bouras C, Kövari E.

J Alzheimers Dis. 2014;39(1):115-20. doi: 10.3233/JAD-131289.

Personalized medicine in neurodegenerative diseases: how far away?

Gotovac K, Hajnšek S, Pašić MB, Pivac N, Borovečki F.

Mol Diagn Ther. 2014 Feb;18(1):17-24. doi: 10.1007/s40291-013-0058-z.

The mild cognitive impairment stage of dementia with Lewy bodies and Parkinson disease: a comparison of cognitive profiles

Yoon JH, Lee JE, Yong SW, Moon SY, Lee PH.

Alzheimer Dis Assoc Disord. 2014 Apr-Jun;28(2):151-5. doi: 10.1097/WAD.0000000000000007.

Gene-based therapies in Parkinson's disease

Allen PJ, Feigin A.

Neurotherapeutics. 2014 Jan;11(1):60-7. doi: 10.1007/s13311-013-0233-2.

Clinimetric evaluation of the Simpson-Angus Scale in older adults with schizophrenia

Blanchet PJ, Rompré PH.

J Clin Psychopharmacol. 2014 Feb;34(1):36-9. doi: 10.1097/JCP.0b013e3182a6a2e3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias